Peru to test China Sinopharm's Covid-19 vaccine in Phase 3 trial
The experimental vaccine of CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has already entered Phase 3 testing in United Arab Emirates
FILE PHOTO: The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong, China March 29, 2016. REUTERS/Bobby Yip/File Photo
Health authorities of the Republic of Peru have approved a Phase 3 clinical trial for a potential Covid-19 vaccine developed by China National Biotec Group (CNBG), the company said on Thursday in Chinese social media platform Weibo.
The experimental vaccine of CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has already entered Phase 3 testing in United Arab Emirates.
Phase 3 trials, which usually involve several thousand participants, allow researchers to gather data on the efficacy of potential vaccines for final regulatory approvals.
Keep updated, follow The Business Standard's Google news channel
